Optimizing Pancreatic Cancer Management Using Next Generation Imaging And Liquid Biopsy

Overview

About this study

The purpose of this study is to examine the relationship of ctDNA status and FDG PET/MRI findings with other clinicopathologic variables and standard staging examinations. We will develop a multivariable model combining ctDNA and FDG PET/MRI biomarkers to predict treatment response and survival. In addition, we will define the quantitative thresholds for early chemotherapy switch in patients who do not respond to first-line chemotherapy.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adults ≥ 18 years with biopsy-proven PDA.
  • Localized disease expected to undergo surgical resection following NAT.
  • ECOG performance status of 0-2.
  • Ability to provide informed consent.

Exclusion Criteria: 

  • Non-FDG avid PDA on baseline PET/MRI.
  • Bilirubin > 3.0 mg/dl.
  • Subjects with higher than the weight/size limitations of PET/MRI scanner or with standard contraindications to PET and MRI.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Ajit Goenka, M.D.

Closed-enrolling by invitation

What is this? (?)
"Close"
Not open to everyone who meets the eligibility criteria, but only those invited to participate by the study team.

Contact information:

Kurt Kevin Degillo

degillo.kurt@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20511291

Mayo Clinic Footer